Osiris Therapeutics designated as Orphan Drug title holder by EMA Osiris Therapeutics announced that the European Medicines Agency, or EMA, has designated Osiris as the Orphan Drug title holder for Prochymal. The EU Commission adopted the decision to transfer the designation of Prochymal as an orphan medicinal product under Regulation, or EC, No 141/2000 of the European Parliament and of the Council. The Decision will appear in the EU Community Register of Orphan Medicinal Products.
Piper Jaffray and the Alliance for Regenerative Medicine co-host conference 3rd Annual Regenerative Medicine Investor Day is being held in New York on March 25 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link